Experimental Vaccine Enters Clinical Trials

In the quest for a Zika virus vaccine, the NIH launched the first of 5 clinical trials to test the experimental Zika Purified Inactivated Virus (ZPIV) candidate.
 
ZPIV, based on the same technology used for a Japanese encephalitis vaccine in 2009, contains inactivated Zika virus particles with an intact protein shell, making it recognizable by the immune system. The vaccine has already proven effective in monkeys.
 
The Walter Reed Army Institute of Research (WRAIR) Clinical Trial Center will host the new study, with expected completion by next fall. Another Zika vaccine, based on a less traditional DNA approach, entered trials in August.
Source: NIH